Posted by Michael Wonder on 19 Dec 2019
Request for information on lamotrigine brand change
9 December 2019 - The request, dated 15 November 2019, asked for all and any advice or information or guidance that PHARMAC received or generated about the non-pharmaceutical health care and wider economic costs due to the recent change in the funded brand of lamotrigine.
Before making the decision to move to one funded brand of lamotrigine (Logem), PHARMAC got expert advice from health care professionals who work directly with people with epilepsy and mental health conditions, to make sure it would be appropriate for people to change brands of lamotrigine.
